Slide 1: Q3 2025 Interim Report
Q3 2025 Interim Report Senzime AB (publ.) Jan-Sept 2025
Slide 2: Nine months 2025: Strong growth and clear steps towards profitability
Nine months 2025: Strong growth and clear steps towards profitability Jan-Sept 2025 revenues (MSEK) 80 1 80% growth in constant currencies 70 2 Sensor deliveries grew 78% 60 50 55 3 Underlying Gross Margin strengthened 40 30 OPEX stable at plan 33 4 20 16 EBITDA improved by 20% 10 21 5 5 11 8 5 0 20
Slide 3: Deliveries of TetraGraph monitors keeps growing - driving sales of disposable sensors
Deliveries of TetraGraph monitors keeps growing - driving sales of disposable sensors Total delivered units of TetraGraph systems Shipped sensors (units) accumulated since Q1 2020 5,000 800,000 4,500 553 700,000 365,535 (205,590) 4,000 TetraGraphs TetraSens sensors sold delivered 600,000 last 12 mon
Slide 4: We continue to lead the segment and be one of the fastest growing medical device companies
We continue to lead the segment and be one of the fastest growing medical device companies on Nasdaq Stockholm Net sales rolling 12-months (kSEK) Net Sales Disposables rolling 12-months kSEK) 90,000 60,000 80,000 50,000 70,000 60,000 40,000 50,000 30,000 40,000 30,000 20,000 20,000 10,000 10,000 0 0
Slide 5: Actuals, including currency effects: Financial results
Actuals, including currency effects: Financial results Q3 Q1-Q3 TOT YEAR TSEK 2025 2024 2025 2024 2024 Net Sales 26,478 17,406 75,673 44,443 58,477 Sales Growth (%) 52.1 90.1 70.3 78.5 63.6 Gross margin excl. amortization (%) 61.2 63.0 62.9 63.5 64.4 Total OPEX 36,642 34,366 114,147 111,195 151,855
Slide 6: Product and market mix: Strong growth in all markets
Product and market mix: Strong growth in all markets Jan-Sept 2025 Q3 2025 Currency Reported adjusted TSEK 2025 2024 Growth Growth US 54,774 33,127 65% 76% Net Sales by product group (Q3) Net Sales by region (Q3) Devices/other 22,910 12,940 77% 89% Europ e 12% Disposables 31,864 20,188 58% 68% Dev i
Slide 7: Winning market shares: Selected key US TetraGraph installations in 2025
Winning market shares: Selected key US TetraGraph installations in 2025 Pacific North-West Win of the world’s based hospital system leading hospital system Contract includes an initial order of 65 next- Installation of Next-Gen Northern MidWest based generation TetraGraph systems for TetraGraph moni
Slide 8: Contract with US Department of Defense
Contract with US Department of Defense “We are proud to be selected as the trusted supplier of our neuromuscular monitoring system to the most prestigious military hospital in the US. This contract is the result of our relentless commitment to patient safety, our scientific leadership, and our organ
Slide 9: US snapshot: Utilization rate of TetraGraph at leading hospitals in the US
US snapshot: Utilization rate of TetraGraph at 5 leading hospitals in the US. Sensors used per week. Sensors per TetraGraph and week 7 YTD 2024 sensors /week/TG • These 5 leading accounts (“The 5”) 6 YTD 2025 sensors/week/TG have approx. 350 TetraGraph Units 5 • All are running and have upgraded to
Slide 10: Senzime @ 2025 ANESTESIOLOGY congress
Senzime @ 2025 ANESTESIOLOGY congress 1. Senzime is the clear industry leader, and we have an extraordinary team 2. We have the Key Opinion Leader backing to succeed 3. Presented research proves the TetraGraph has significantly higher utilization rates and competing solutions
Slide 11: Personalizing anesthesia. Now available in EU and US
Personalizing anesthesia. Now available in The TetraGraph just got even smarter, EU and US refined by science and billions of data points Introducing the EMGINE Software Suite Advancing Neuromuscular Monitoring • 7th Generation algorithm refined based on over 6 billion real-world data points for acc
Slide 12: Customer testimonial: Next-generation TetraGraph in community hospital
“Bringing the Next-generation TetraGraph into our community hospital has transformed how we manage neuromuscular block. It has improved patient safety, standardized our practices, and reduced our annual drug spend by more than $100,000.” Dr. Aaron Persinger Anesthesiologist, Boulder Valley Anesthesi
Slide 13: Intelmarket Research: Senzime frontrunner with approximately 15% market share
“Senzime AB has emerged as a frontrunner in this space, leveraging its proprietary electromyography (EMG) technology to Quantitative Neuromuscular capture approximately 15% of the market Monitor Market Growth Analysis, Dynamics, Key Players and share in 2024” Innovations, Outlook and Forecast 2025-2
Slide 14: The QUANTUM Study
The largest neuromuscular outcome study to date started in Texas The QUANTUM Study Quantitative versus qualitative neuromonitoring of neuromuscular block for non-cardiothoracic surgery 14
Slide 15: New Pediatric Guidelines for Neuromuscular Monitoring
New Pediatric Guidelines for Neuromuscular Monitoring ”Recommending quantitative monitoring with EMG-based rather than AMG-based devices due to higher accuracy and reliability of decurarisation monitoring”
Slide 16: Advancements on the Japanese market
Advancements on the Japanese market New Japanese Guidelines for Neuromuscular Monitoring ”Recommending the use of a quantitative monitor when using paralytic drugs”
Slide 17: Integration and Connectivity to industry leaders
Integration and Connectivity to industry leaders TetraGraph Xcom and TetraHub – For seamless data integration Enables connectivity to a wide range of supported external hubs and monitors, ensuring the automatic transmission and display of Latest additions to quantitative TOF monitoring data. The Xco
Slide 18: Underlying Gross Margin improves, but US tariffs and currencies affect Gross Margins in 2025
Underlying Gross Margin improves, but US tariffs and currencies affect Gross Margins in 2025 • Q3 underlying gross margin at 69.2%, Q3 Q1-Q3 and Q1-Q3 at 68.1% (63.5%) driven by Underlying Gross Margin 69.2% 68,1% lower production costs and product mix. Negatively contributing effects to Gross Margi
Slide 19: Operating expenses stable and on plan
Operating expenses stable and on plan Quarterly Direct Operating Expenses (KSEK) 45,000 39,573 39,872 • Q3 direct OPEX of 37,060 kSEK (34,419) 40,000 36,930 37,182 36,430 37,060 in-line with plans despite significant 35,332 35,000 33,903 investments in US commercial team 31,291 and global marketing
Slide 20: Clear steps toward profitability
Clear steps toward profitability Q1-Q3 EBITDA (KSEK) 0 -10,000 20% • Q1-Q3 EBITDA improved by 20% to -63,806 kSEK (-79,657) -20,000 improvement of mainly driven by higher sales and stable OPEX. EBITDA in YTD -30,000 • Q3 EBITDA improved by 8% to -19,395 kSEK (-22,253) mainly -40,000 driven by higher
Slide 21: This is Senzime - a leader in personalized anesthesia
This is Senzime - a leader in personalized anesthesia, backed by over 40 years of science, extensive clinical data and over 100 patents Personalizing anesthesia by algorithm-powered monitoring to secure precise dosing of paralytic drugs empowering clinicians with real-time signals to confidently det
Slide 22: Use of paralytic drugs in anesthesia - prone to serious complications and costs
Use of paralytic drugs in anesthesia – prone to serious complications and costs 100 million Paralyzes patients a year receive patients in ~45 paralytic drugs seconds 87% of patients ~40% leave the OR with are overdosed with with residual paralysis, at reversals, and 13% risk of post-operative underd
Slide 23: The solution to safe anesthesia: Senzime's TetraGraph
The solution to safe anesthesia: Senzime’s TetraGraph, the new gold standard in modern surgery EMG-based monitoring has proved to eliminate complications related to paralytic drugs, reduce drug costs with 70% and secure safe deep block during surgery.
Slide 24: The Goals and Outlook
The Goals and Outlook 2025 outlook The mission In February this year, we communicated a full-year 2025 sales range To safeguard every patient's journey, estimate based on a USD/SEK exchange rate that was at the time about 15 from anesthesia to recovery. We do percent higher than it is today. this by
Slide 25: Wrapping up - the triad and what it's all about
Wrapping up – the triad and what it’s all about Strong growth and strengthened market shares Driving patient safety and reduced healthcare costs Clear steps STRONG RETURNS P towards profitability
Slide 26: Safeguard every patient's journey, from anesthesia to recovery
So, join us on our mission to Safeguard every patient's journey, from anesthesia to recovery. Questions? philip.siberg@senzime.com